QUANTERIX CORP (QTRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for QTRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| QTRX | President, Chief Executive Officer and Director | 59 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ARVN | Director | 59 | ["30 years of progressive responsibility in pharmaceuticals and medical services","20 years of commercial leadership across healthcare tech, life sciences and pharmaceuticals"] | [] | 2026 |
| EXAS | Former Chief Commercial Officer | [] | [] | 2025 | |
| ILMN | Chief Commercial Officer | 58 | ["Chief Commercial Officer, Illumina","EVP and Chief Commercial Officer, Exact Sciences","President & CEO, US & Canada, GE Healthcare"] | [] | 2025 |
Biography sourced from the proxy statement filing.
On January 8, 2026, we entered into an employment agreement with Mr. Cunningham in connection with his appointment as President and Chief Executive Officer effective as of January 19, 2026. Under the agreement, Mr. Cunningham is entitled to an initial annualized base salary of $750,000 and eligibility for an annual performance bonus with an annual bonus target of up to 100% of his base salary. The agreement also provides for a sign-on cash payment of $600,000 payable within 30 days following Mr. Cunningham s start date. If Mr. Cunningham voluntarily terminates his employment without good reason within one year of the start date, Mr. Cunningham will be required to repay 50% of the sign-on cash payment, and if his employment is terminated for cause within one year of the start date, he will be required to repay the sign-on cash payment in full. In connection with his appointment, Mr. Cunningham also received long-term equity incentive awards consisting of (a) RSUs covering 1,070,000 shares of Company common stock, subject to time-based vesting (the Time-Based RSUs ) and (b) RSUs covering 813,750 shares of Company common stock, subject to performance-based vesting (the Performance-Based RSUs ). The Time-Based RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. Cunningham s start date. One-fifth of the Performance-Based RSUs will vest on the later of (i) the date that the volume weighted average price of the Company s common stock on the Nasdaq Global Market (or other applicable national securities exchange) ( VWAP ) equals or exceeds $10 per share for 30 consecutive trading days prior to the second anniversary of Mr. Cunningham s start date and (ii) the first anniversary of his start date, two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $15 per share for 30 consecutive trading days prior to the third anniversary of Mr. Cunningham s start date and (ii) the second anniversary of his start date, and the remaining two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $20 per share for 30 consecutive trading days prior to the fourth anniversary of Mr. Cunningham s start date and (ii) the third anniversary of his start date. In the event of a change-in-control (as defined in the agreement) in which the consideration payable to a holder of a share of the Company s common stock equals or exceeds $10, $15 or $20, the corresponding tranche(s) of the Performance-Based RSUs will vest as of such change-in-control, and if the consideration payable to a holder of a share of the Company s common stock is between $10 and $15 or between $15 and $20, then vesting shall be determined by straight line interpolation within the applicable tranche. If Mr. Cunningham s employment is terminated by the Company without cause or he resigns for good reason, he will receive continued payment of his base salary for 12 months, payment of an amount equal to his annual target bonus for the year of termination, acceleration of any of the unvested portion of the Time-Based RSUs that would have vested during the 12-month severance period, and subsidized health benefits during such severance period. If Mr. Cunningham s employment is terminated by the Company without cause or he resigns for good reason in connection with a change-in-control, Mr. Cunningham s base salary continuation will last for 24 months, all of his outstanding but unvested equity awards subject to time-based vesting will become fully vested, and his outstanding but unvested Performance-Based RSUs will remain eligible for vesting in connection with such change-in-control.